Form 4: Arteris CEO Charles Janac Reports Sales of Company Stock Under Pre-Arranged Trading Plans

Arteris, Inc. President and CEO, Charles Janac, reported the sale of 21,286 shares of common stock in two separate transactions in late June and early July 2025, executed under pre-established 10b5-1 trading plans.

Summary

• Charles Janac, President and CEO, Director, and 10% Owner of Arteris, Inc. (AIP), reported changes in beneficial ownership of the company's common stock.
• On June 27, 2025, 18,620 shares of Common Stock were sold at a weighted average price of $10.0207 per share. This transaction was executed pursuant to a 10b5-1 trading plan adopted on February 27, 2024.
• On July 1, 2025, an additional 2,666 shares of Common Stock were sold at a weighted average price of $9.0918 per share. This transaction was executed pursuant to a separate 10b5-1 trading plan adopted on March 5, 2025.
• The total number of shares sold across both transactions is 21,286.
• Following these transactions, beneficial ownership includes 9,889,071 shares indirectly through Bayview Legacy, LLC, 302,998 shares held directly, and 56,252 shares indirectly through the Charles and Lydia Janac Trust.

Sentiment

Score: 4

Explanation: The document reports insider sales, which can be viewed negatively by the market, especially given the slight decline in sale price between the two transactions. However, the sales represent a very small fraction of the reporting person's total beneficial ownership and were conducted under pre-arranged 10b5-1 plans, which mitigates the negative perception of opportunistic trading.

Positives

• The reported transactions were executed under Rule 10b5-1 trading plans, indicating pre-scheduled sales not based on immediate material non-public information.

Negatives

• Insider sales, even if pre-planned, can sometimes be interpreted by the market as a signal of reduced confidence or a need for liquidity by the insider.
• The second sale on July 1, 2025, occurred at a lower weighted average price ($9.0918) compared to the first sale on June 27, 2025 ($10.0207), indicating a decline in the stock price over that period.

Risks

• Potential negative market perception due to insider sales, despite being pre-planned, which could lead to short-term stock price volatility.
• The declining sale price between the two transactions could indicate existing or anticipated downward pressure on the stock price.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance, strategic direction, or financial estimates. It solely reports insider trading activity.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. While it does not directly relate to broader industry trends, insider sales are closely watched by investors as a potential indicator of management's confidence in the company's future prospects relative to its valuation. The use of 10b5-1 plans is a common practice for insiders to manage their stock holdings in a compliant manner, mitigating the perception of trading on inside information.

Comparison to Industry Standards

• This document reports insider stock sales, which are standard disclosures for publicly traded companies in all industries.
• There are no specific financial results or operational metrics within this filing to compare against industry benchmarks or specific comparable companies/projects.
• The use of 10b5-1 plans for insider sales is a widely accepted and standard practice across industries for managing compliance and avoiding accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: May interpret insider sales as a signal, potentially influencing their investment decisions. The use of 10b5-1 plans provides transparency and reduces concerns about unfair trading, but the lower price of the second sale could still be a concern.

Next Steps

• The document does not specify any future actions, events, or milestones for the company or the reporting person beyond the reported transactions.

Key Dates

Recommendation

Keywords

Arteris Inc., AIP, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Charles Janac, Beneficial Ownership, SEC Filing, Corporate Governance